0001493152-23-046183.txt : 20231227 0001493152-23-046183.hdr.sgml : 20231227 20231227074040 ACCESSION NUMBER: 0001493152-23-046183 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20231227 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231227 DATE AS OF CHANGE: 20231227 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Matinas BioPharma Holdings, Inc. CENTRAL INDEX KEY: 0001582554 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 463011414 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38022 FILM NUMBER: 231514632 BUSINESS ADDRESS: STREET 1: 1545 ROUTE 206 SOUTH STREET 2: SUITE 302 CITY: BEDMINSTER STATE: NJ ZIP: 07921 BUSINESS PHONE: 908-484-8805 MAIL ADDRESS: STREET 1: 1545 ROUTE 206 SOUTH STREET 2: SUITE 302 CITY: BEDMINSTER STATE: NJ ZIP: 07921 8-K 1 form8-k.htm
false 0001582554 0001582554 2023-12-27 2023-12-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): December 27, 2023

 

 

 

MATINAS BIOPHARMA HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-38022   46-3011414
(State or other jurisdiction
of incorporation) 		  (Commission
File Number) 		  (IRS Employer
ID Number)

 

1545 Route 206 South, Suite 302

Bedminster, New Jersey

  07921
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (908) 484-8805

 

Not Applicable

(Former name or former address, if changed since last report.)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class   Trading Symbol   Name of Each Exchange on Which Registered
Common Stock   MTNB   NYSE American

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 7.01 Regulation FD Disclosure.

 

On December 27, 2023, Matinas BioPharma Holdings, Inc. (the “Company”) issued a press release announcing results from a series of in vivo studies demonstrating successful oral delivery of two lipid nanocrystal (“LNC”)-formulated small single-strand oligonucleotides that specifically target key inflammatory cytokines TNFα and IL-17A in well-established and validated animal models that mimic acute inflammatory responses seen in human diseases. A copy of the press release is furnished as Exhibit 99. 1 hereto and incorporated herein by reference.

 

The information in this Item 7.01 and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

Item 8.01. Other Events.

 

On December 21, 2023, the Company announced results from a series of in vivo studies demonstrating successful oral delivery of two LNC-formulated small single-strand oligonucleotides that specifically target key inflammatory cytokines TNFα and IL-17A in well-established and validated animal models that mimic acute inflammatory responses seen in human diseases.

 

Acute Colitis Study (“TNFα”)

 

A dextran sulfate sodium (“DSS”)-induced murine colitis model was used to evaluate an orally administered LNC-delivered small oligonucleotide that specifically targets TNFα mRNA synthesis. Colon tissue TNFα mRNA levels, as assessed by quantitative real-time PCR analysis, were lower following orally administered active LNCs, resulting in statistically significant reductions of serum TNFα levels by 37% compared with diseased, but untreated animals. Importantly, clinical disease activity scores at key time points in the studies were also significantly improved with an active LNC formulation.

 

Acute Psoriasis Study (“IL-17A”)

 

An imiquimod (“IMQ”)-induced murine psoriasis model was used to evaluate an orally administered, LNC-delivered small oligonucleotide designed to inhibit IL-17A mRNA synthesis, which contributes significantly to the progression of psoriatic skin lesions. Similar to the DSS colitis model, skin tissue levels of IL-17A mRNA in the IMQ psoriasis model were lower with orally administered active LNCs compared with IMQ alone. In this model, while IL-17A serum levels were not expected to change, improvement was demonstrated in clinical disease markers of skin redness and scaling, further validating the biological activity of these small oligonucleotides.

 

Additional tissue and histologic analyses from both studies are ongoing and the Company plans to present these data at future scientific meetings.

 

Forward- Looking Statements

 

This Current Report on Form 8-K contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s business activities, the Company’s strategy and plans, the potential of the Company’s LNC platform technology, and the future development of its product candidates, including MAT2203, the Company’s ability to identify and pursue development, licensing and partnership opportunities for its products, including MAT2203, or platform delivery technologies on favorable terms, if at all, and the ability to obtain required regulatory approval and other statements that are predictive in nature, that depend upon or refer to future events or conditions. All statements other than statements of historical fact are statements that could be forward-looking statements.

 

These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expects,” “anticipates,” “intends,” “plans,” “could,” “believes,” “estimates” and similar expressions. These statements involve known and unknown risks, uncertainties and other factors which may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, the Company’s ability to continue as a going concern, the Company’s ability to obtain additional capital to meet its liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials of its product candidates; the Company’s ability to successfully complete research and further development and commercialization of its product candidates; the uncertainties inherent in clinical testing; the timing, cost and uncertainty of obtaining regulatory approvals; the Company’s ability to protect its intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company’s products; and the other factors listed under “Risk Factors” in the Company’s filings with the SEC, including Forms 10-K, 10-Q and 8-K. Investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. Except as may be required by law, the Company does not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. The Company’s product candidates are all in a development stage and are not available for sale or use.

 

Item 9.01 Financial Statements and Exhibits.

 

Exhibit No.   Description
99.1   Press Release, dated December 27, 2023
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

-2-
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  MATINAS BIOPHARMA HOLDINGS, INC.
     
Dated: December 27, 2023 By: /s/ Jerome D. Jabbour
  Name: Jerome D. Jabbour
  Title: Chief Executive Officer

 

-3-

 

 

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

 

Matinas BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small Oligonucleotides

 

In an acute colitis model, data show statistically significant knockdown of elevated levels of serum TNFα, reductions in tissue TNFα mRNA and improvement in disease activity scores

 

In an acute psoriasis model, data show reductions in tissue IL-17A mRNA and improvement in clinical disease markers including skin lesions

 

BEDMINSTER, N.J. (December 27, 2023) – Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform technology, announces results from a series of in vivo studies demonstrating successful oral delivery of two LNC-formulated small single-strand oligonucleotides that specifically target key inflammatory cytokines TNFα and IL-17A in well-established and validated animal models that mimic acute inflammatory responses seen in human diseases.

 

“These studies demonstrate successful oral delivery and biological activity of two different LNC-formulated small oligonucleotides targeting inflammatory cytokines with reductions in tissue cytokine mRNA in both colitis and psoriasis, along with significant reductions in serum TNFα levels in colitis. Commensurate improvements in clinical disease markers and scores were also documented in both models,” said James Ferguson, M.D., Matinas’ Chief Medical Officer.

 

“While additional study is warranted, the successful oral delivery of small oligonucleotides is very exciting and we believe these data demonstrate how Matinas’ LNC platform could be used for the oral delivery of functional small oligonucleotides with potential therapeutic applications,” Dr. Ferguson added. “Importantly, the unique nature of the particular oligonucleotides evaluated in these studies, which interfere with cytokine synthesis rather than simply targeting the cytokine itself, creates additional opportunities for potential future applications of LNC-delivered therapeutics, either alone or in combination with other therapeutics with different mechanisms of action.”

 

Earlier this year, Matinas established the in vitro potency of these proprietary oligonucleotides and their LNC formulations in knocking down their respective cytokine targets in cultured cells. Both were advanced to in vivo studies to evaluate meaningful biological activity in relevant disease models.

 

Acute Colitis Study (TNFα)

 

A dextran sulfate sodium (DSS)-induced murine colitis model was used to evaluate an orally administered LNC-delivered small oligonucleotide that specifically targets TNFα mRNA synthesis. Colon tissue TNFα mRNA levels, as assessed by quantitative real-time PCR analysis, were lower following orally administered active LNCs, resulting in statistically significant reductions of serum TNFα levels by 37% compared with diseased, but untreated animals. Importantly, clinical disease activity scores at key time points in the studies were also significantly improved with an active LNC formulation.

 

 
 

 

Acute Psoriasis Study (IL-17A)

 

An imiquimod (IMQ)-induced murine psoriasis model was used to evaluate an orally administered, LNC-delivered small oligonucleotide designed to inhibit IL-17A mRNA synthesis, which contributes significantly to the progression of psoriatic skin lesions. Similar to the DSS colitis model, skin tissue levels of IL-17A mRNA in the IMQ psoriasis model were lower with orally administered active LNCs compared with IMQ alone. In this model, while IL-17A serum levels were not expected to change, improvement was demonstrated in clinical disease markers of skin redness and scaling, further validating the biological activity of these small oligonucleotides.

 

Additional tissue and histologic analyses from both studies are ongoing and the Company plans to present these data at future scientific meetings.

 

“We believe that our proprietary encapsulation and oral delivery methods could be applied to other small oligonucleotides, including RNAi therapeutics such as siRNA and antisense oligonucleotides,” said Jerome D. Jabbour, Chief Executive Officer of Matinas. “While a variety of methods for administering small oligonucleotides exist, most are primarily directed to the liver, and none provide oral administration and delivery capabilities. The opportunity to orally deliver small oligonucleotides with extra-hepatic targeting could be key differentiating features in rapidly advancing anti-inflammatory therapy.

 

“We plan to further review the data from these inflammatory disease models to determine the best path forward for this program,” he added. “Further study and optimization of these LNC-delivered small oligonucleotides will be required to assess the most appropriate therapeutic targets and the associated magnitude of benefit.”

 

About Matinas BioPharma

 

Matinas BioPharma is a biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology.

 

Matinas’ lead LNC-based therapy is MAT2203, an oral formulation of the broad-spectrum antifungal drug amphotericin B, which although highly potent, can be associated with significant toxicity. Matinas’ LNC platform provides oral delivery of amphotericin B without the significant nephrotoxicity otherwise associated with IV-delivered formulations. MAT2203 also allows for safe, longer-term use outside of a hospital setting, which could have substantial favorable pharmacoeconomic impact. MAT2203 was successfully evaluated in the completed Phase 2 EnACT study in cryptococcal meningitis, meeting its primary endpoint and achieving robust survival. MAT2203 will be further evaluated as an oral step-down monotherapy treatment following IV amphotericin B in a single pivotal Phase 3 study in the treatment of aspergillosis in persons with limited treatment options who are unable to be treated with azoles for reasons related to drug-drug interactions, resistance or for whom these antifungal agents are unable to be used for other clinical reasons.

 

In addition to MAT2203, preclinical and clinical data have demonstrated that this novel technology can potentially provide solutions to many of the challenges standing in the way of achieving safe and effective intracellular delivery of both small molecules and larger, more complex molecular cargos such as small oligonucleotides such as ASOs and siRNA. The combination of its unique mechanism of action and flexibility with routes of administration (including oral) positions Matinas’ LNC technology to potentially become a preferred next-generation orally available intracellular drug delivery platform. For more information, please visit www.matinasbiopharma.com.

 

 
 

 

Forward-looking Statements

 

This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to our business activities, our strategy and plans, the potential of our LNC platform technology, and the future development of its product candidates, including MAT2203, the Company’s ability to identify and pursue development, licensing and partnership opportunities for its products, including MAT2203, or platform delivery technologies on favorable terms, if at all, and the ability to obtain required regulatory approval and other statements that are predictive in nature, that depend upon or refer to future events or conditions. All statements other than statements of historical fact are statements that could be forward-looking statements. Forward-looking statements include words such as “expects,” “anticipates,” “intends,” “plans,” “could,” “believes,” “estimates” and similar expressions. These statements involve known and unknown risks, uncertainties and other factors which may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to continue as a going concern, our ability to obtain additional capital to meet our liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials of our product candidates; our ability to successfully complete research and further development and commercialization of our product candidates; the uncertainties inherent in clinical testing; the timing, cost and uncertainty of obtaining regulatory approvals; our ability to protect the Company’s intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company’s products; and the other factors listed under “Risk Factors” in our filings with the SEC, including Forms 10-K, 10-Q and 8-K. Investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this release. Except as may be required by law, the Company does not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Matinas BioPharma’s product candidates are all in a development stage and are not available for sale or use.

 

Investor Contact

 

LHA Investor Relations

Jody Cain

Jcain@lhai.com

310-691-7100

 

# # #

 

 

 

 GRAPHIC 3 ex99-1_001.jpg begin 644 ex99-1_001.jpg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end EX-101.SCH 4 mtnb-20231227.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 mtnb-20231227_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 mtnb-20231227_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.4
Cover
Dec. 27, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Dec. 27, 2023
Entity File Number 001-38022
Entity Registrant Name MATINAS BIOPHARMA HOLDINGS, INC.
Entity Central Index Key 0001582554
Entity Tax Identification Number 46-3011414
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 1545 Route 206 South
Entity Address, Address Line Two Suite 302
Entity Address, City or Town Bedminster
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07921
City Area Code (908)
Local Phone Number 484-8805
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol MTNB
Security Exchange Name NYSEAMER
Entity Emerging Growth Company false
XML 8 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001582554 2023-12-27 2023-12-27 iso4217:USD shares iso4217:USD shares false 0001582554 8-K 2023-12-27 MATINAS BIOPHARMA HOLDINGS, INC. DE 001-38022 46-3011414 1545 Route 206 South Suite 302 Bedminster NJ 07921 (908) 484-8805 false false false false Common Stock MTNB NYSEAMER false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

JQ"(6,P$ "(" / " M 6\0 !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4 " 3/9M7)!Z;HJT #X M 0 &@ @ '/$0 >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E M;'-02P$"% ,4 " 3/9M799!YDAD! #/ P $P @ &T L$@ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 "0 ) #X" #^$P ! end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.4 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://matinasbiopharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm mtnb-20231227.xsd mtnb-20231227_lab.xml mtnb-20231227_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form8-k.htm": { "nsprefix": "MTNB", "nsuri": "http://matinasbiopharma.com/20231227", "dts": { "inline": { "local": [ "form8-k.htm" ] }, "schema": { "local": [ "mtnb-20231227.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "mtnb-20231227_lab.xml" ] }, "presentationLink": { "local": [ "mtnb-20231227_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://matinasbiopharma.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-12-27", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-27", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true } } }, "tag": { "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://matinasbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001493152-23-046183-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-046183-xbrl.zip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end